Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.

Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resis...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dhiraj Kumar Singh, Sultan Tousif, Ashima Bhaskar, Annu Devi, Kriti Negi, Barnani Moitra, Anand Ranganathan, Ved Prakash Dwivedi, Gobardhan Das
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Acceso en línea:https://doaj.org/article/93fb6bb20ab94443ba71835315feeff6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!